Related Experiment Video
Updated: Aug 27, 2025

09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
33.9K
Percutaneous coronary intervention in a patient with homozygous RNF213 variant
Fumiaki Yashima1, Mizuki Momoi2, Takashi Kawakami2
1Department of Cardiology, Saiseikai Utsunomiya Hospital, Tochigi 3210974, Japan.
European Heart Journal. Case Reports
|September 23, 2022
Abstract
No abstract available in PubMed .
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
21
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
637
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
637

